bioRxiv · 10.1101/2023.06.18.545492
Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis
Abstract
Contezolid is a new oxazolidinone with in vitro and in vivo activity against Mycobacterium tuberculosis comparable to that of linezolid. Pre-clinical and clinical safety studies suggest it may be less toxic than linezolid, making contezolid a potential candidate to replace linezolid in treatment of drug-resistant tuberculosis. We evaluated the dose-ranging activity of contezolid, alone and in combination with bedaquiline and pretomanid, and compared it with linezolid at similar doses, in an established BALB/c mouse model of tuberculosis. Contezolid had an MIC of 1 {micro}g/ml, similar to linezolid, and exhibited similar bactericidal activity in mice. Contezolid-resistant mutants selected in vitro had 10-fold increases in contezolid MIC and harbored mutations in the mce3R gene. These mutants did not display cross-resistance to linezolid. Our results indicate that contezolid has potential to replace linezolid in regimens containing bedaquiline and pretomanid and likely other regimens.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Almeida, D. V., Li, S.-Y., Lee, J., Hafkin, B., Mdluli, K., Fotouhi, N., Nuermberger, E.. 2023-06-19. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis. https://doi.org/10.1101/2023.06.18.545492
Cite the original work for its findings. Save a collection to share your selection of sources.